AstraZeneca sets $80B revenue target, goal of 20 new drugs by 2030

AstraZeneca on Tuesday unveiled a roadmap for its business through the end of the decade, setting a lofty goal of achieving $80 billion in total revenue by 2030, up about 75% from $45.8 billion in 2023.